Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Craddock, Charles  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Craddock C. Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future. Br J Haematol. 2020;191(4):568-572.
Maffini E, Ngoya M, Galimard J-E, Harbi S, Kröger N, Platzbecker U, Sengeloev H, Craddock C, Potter V, Choi G, et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
B
Barrett J, Craddock C. Bone marrow transplantation in the United Kingdom - past, present and future. Br J Haematol. 2020;191(4):612-616.
C
de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, et al. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018.
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022.
M
Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, Cornelissen JJ, Salmenniemi U, Yakoub-Agha I, Reményi P, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.
P
Loke J, McCarthy N, Jackson AE, Siddique S, Hodgkinson A, Mason J, Crawley CR, Gilleece M, Peniket AJ, Protheroe R, et al. Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS. Blood Adv. 2023.
S
Kinsella FAM, Maroto MAL, Loke J, Craddock C. Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2024.
T
Craddock C. Transplant in AML with measurable residual disease: proceed or defer?. Hematology Am Soc Hematol Educ Program. 2022;2022(1):528-533.
V
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EMaria, Versluis J, Schroeder T, Blau IWolfgang, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, et al. Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease. Leuk Res. 2019;83:106173.
W
Craddock C, Raghavan M. Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?. Curr Opin Hematol. 2018.